Prescribing Information
Healthcare professionals are asked to report any adverse events via their national reporting system (see Section 4.8 of SmPC). In the UK reporting forms and information can be found at
or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Kyowa Kirin Ltd on +44 (0)1896 664000, email: medinfo@kyowakirin.com
touchMEETING HIGHLIGHTS Connecting Symptoms to Quality of Life: The Importance of Considering Patient Wellbeing when Managing Cutaneous T-Cell Lymphoma (CTCL)
From the Kyowa Kirin-sponsored symposium at the EORTC-CLTG Meeting 2023. Watch leading experts discuss the connections between CTCL symptoms and patient quality of life. This session will offer valuable insights that may positively impact your clinical practice.
Adverse Events
Adverse Events
Healthcare professionals are asked to report any adverse events via their national reporting system (see Section 4.8 of SmPC). In the UK reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Kyowa Kirin Ltd on +44 (0)1896 664000, email: medinfo@kyowakirin.com
Overview & Learning Objectives
Overview
Leading experts discuss the connections between CTCL symptoms and patient quality of life, and what this means for clinical decision making during treatment. This session will offer valuable insights that may positively impact your clinical practice.
Learning Objectives
By watching this activity, participants will be able to:
- Hear from a patient advocacy group (PAG) representative about how cutaneous T-cell lymphoma (CTCL) impacts the day-to-day lives of patients
- Understand expert perspectives on what patient quality of life (QoL) means for clinical decision making during CTCL treatment
- Appreciate the latest real-world evidence on targeted therapy with mogamulizumab for treatment of mycosis fungoides (MF) and Sézary syndrome (SS)
About Faculty
Prof. Maarten Vermeer
Head of the Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands
Prof. Maarten Vermeer discloses: Unrestricted research grants from Kyowa Kirin, Recordati and Takeda. Advisory board fees from Galderma, Innate Pharma and Kyowa Kirin. Speaker fees from 4SC Takeda and Kyowa Kirin.
Susan Thornton
Patient Advocacy Group (PAG) Representative and CEO, Cutaneous Lymphoma Foundation, Philadelphia, USA
Susan Thornton has no interests/relationships or affiliations to disclose in relation to this activity.
Dr Kevin Molly
Consultant Dermatologist, Trinity College Dublin, Dublin, Ireland
Dr Kevin Molly discloses: Honorarium from Almirall, Kyowa Kirin, Mallinckrodt, Recordati Rare Diseases and Takeda. Consultant for Kyowa Kirin.
Prof. Chalid Assaf
Director of the Department of Dermatology, Helios Klinikum Krefeld, Krefeld, Germany
Prof. Chalid Assaf discloses: Consultancy/advisory honorarium from 4SC, Helsinn, Kyowa Kirin, Recordati Rare Diseases, Stemline and Takeda.
